Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 689–690 | Cite as

ASO Author Reflections: Metaplastic Breast Cancer—The Case for Doing Less and More

  • Oluwadamilola M. FayanjuEmail author
ASO Author Reflections
  • 72 Downloads

Notes

Acknowledgment

Dr. Fayanju is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under Award Number 5KL2TR001115 (PI: Svetkey) and by the Duke Cancer Institute through NIH grant P30CA014236 (PI: Kastan).

Disclosures

Oluwadamilola M. Fayanju has no conflicts of interest to disclose.

References

  1. 1.
    Krings G, Chen YY. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. Modern pathology. 2018;31(11):1661–74.CrossRefGoogle Scholar
  2. 2.
    Schroeder MC, Rastogi P, Geyer CE Jr, Miller LD, Thomas A. Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in surveillance, epidemiology, and end results (SEER) 2010–2014. Oncologist. 2018;23(4):481–8.CrossRefGoogle Scholar
  3. 3.
    Ong CT, Campbell BM, Thomas SM, et al. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database. Ann Surg Oncol. 2018;25(8):2249–60.CrossRefGoogle Scholar
  4. 4.
    Edenfield J, Schammel C, Collins J, Schammel D, Edenfield WJ. Metaplastic breast cancer: molecular typing and identification of potential targeted therapies at a single institution. Clinical Breast Cancer. 2017;17(1):e1–10.CrossRefGoogle Scholar
  5. 5.
    Murphy BL, Fazzio RT, Hoskin TL, et al. Management of the axilla in metaplastic breast carcinoma. Gland Surgery. 2018;7(2):200–6.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of SurgeryDuke University Medical CenterDurhamUSA
  2. 2.Duke Cancer InstituteDurhamUSA

Personalised recommendations